WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#:406507
CAS#:1504583-00-9
Description:DAT-230 is a promising microtubule inhibitor that has great potential for the treatment of fibrosarcoma in vitro and in vivo. DAT-230 exhibited potent anti-proliferative activity against various cancer cells. DAT-230 -treatment in HT-1080 cells resulted in microtubule de-polymerization and G2/M phase arrest preceding apoptosis. Phosphor-cdc2 (thr14/tyr15) reduction, cyclin B1 accumulation and aberrant spindles denoted the cyclin B1-cdc2 complex active and M phase arrest in HT-1080 cells treated with DAT-230. Apoptosis induced by DAT-230 was related with the activation of caspase-9, caspase-3 and PARP cleavage, which were at the downstream of mitochondria.
DAT-230 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.
MedKoo Cat#: 406507Name: DAT-230CAS#: 1504583-00-9Chemical Formula: C20H21NO2SExact Mass: 339.1293Molecular Weight: 339.45Elemental Analysis: C, 70.77; H, 6.24; N, 4.13; O, 9.43; S, 9.45
Synonym:DAT230; DAT 230; DAT-230.
IUPAC/Chemical Name:2-methoxy-5-(2-(3-methoxy-4,5-dimethylphenyl)thiophen-3-yl)aniline
InChi Key:NPXKFXXMFDKVTM-UHFFFAOYSA-N
InChi Code:InChI=1S/C20H21NO2S/c1-12-9-15(11-19(23-4)13(12)2)20-16(7-8-24-20)14-5-6-18(22-3)17(21)10-14/h5-11H,21H2,1-4H3
SMILES Code:NC1=CC(C2=C(C3=CC(C)=C(C)C(OC)=C3)SC=C2)=CC=C1OC
1: Qiao F, Zuo D, Wang H, Li Z, Qi H, Zhang W, Wu Y.DAT-230, a Novel Microtubule Inhibitor, Induced Aberrant Mitosis and Apoptosis in SGC-7901 Cells.Biol Pharm Bull. 2013;36(2):193-201. PubMed PMID: 23370351.
2: Qiao F, Zuo D, Shen X, Qi H, Wang H, Zhang W, Wu Y. DAT-230, a novel microtubule inhibitor, exhibits potent anti-tumor activity by inducingG2/M phase arrest, apoptosis in vitro and perfusion decrease in vivo to HT-1080.Cancer Chemother Pharmacol. 2012 Aug;70(2):259-70. doi:10.1007/s00280-012-1907-x. Epub2012 Jun 30. PubMed PMID: 22752214.